Dinaciclib for the treatment of breast cancer
- 12 May 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 23 (9) , 1305-1312
Abstract
(2014). Dinaciclib for the treatment of breast cancer. Expert Opinion on Investigational Drugs: Vol. 23, No. 9, pp. 1305-1312.Keywords
This publication has 50 references indexed in Scilit:
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasCancer Chemotherapy and Pharmacology, 2013
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsLeukemia, 2012
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionJournal of Experimental Medicine, 2012
- A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridolCancer Chemotherapy and Pharmacology, 2010
- Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid TumorsClinical Cancer Research, 2009
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursAnnals of Oncology, 2009
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaBlood, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Cell cycle kinases in cancerCurrent Opinion in Genetics & Development, 2007
- A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysBritish Journal of Cancer, 2006